Imugene (ASX:IMU) received AU$20 million from the issuance of senior, unsecured, zero-coupon convertible notes to CVI Investments, representing the first tranche of a AU$46 million capital raise, according to a Wednesday filing with the Australian bourse.
The convertible notes have a five-year maturity, the filing said.
Proceeds will be used to advance the company's immuno-oncology clinical trial pipeline, according to the filing.
Imugene's shares fell nearly 3% in morning trade Wednesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.